Within the recent years, development of cancer chemotherapy and use of more potent immune suppressive drugs as well as immune modulating biological agents, especially anti-TNF compounds, have contributed to an increase in the number of disseminated and/or rapidly progressing “opportunistic AE” in patients with cancer, hematological disorders or chronic inflammatory diseases [7,36,37]. This evidence concerns the gene TNF and cancer.